Ashley Amar
Psychiatry · Waco, TXNPI 1952533325
Payments from drug & device makers
Across 117 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$358
- Xeris Pharmaceuticals, Inc.$183
- Blueprint Medicines Corporation$150
- Novo Nordisk$141
- Sanofi-aventis U.S. LLC$105
- Dexcom, Inc.$104
- plus $944 from 25 others
What the payments were for
- Food & beverage$1,985100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 24 | $358 |
| Xeris Pharmaceuticals, Inc. | 10 | $183 |
| Blueprint Medicines Corporation | 6 | $150 |
| Novo Nordisk | 9 | $141 |
| Sanofi-aventis U.S. LLC | 5 | $105 |
| Dexcom, Inc. | 8 | $104 |
| Corcept Therapeutics | 6 | $100 |
| Biocryst US Sales Co., LLC | 6 | $94 |
| Zealand Pharma US, Inc. | 4 | $89 |
| Abbott | 4 | $77 |
| Bayer | 5 | $72 |
| Teva Pharmaceuticals USA, Inc. | 3 | $52 |
| Pfizer | 4 | $52 |
| Amarin Pharma, Inc. | 3 | $45 |
| Lilly USA, LLC | 2 | $41 |
| Medtronic | 1 | $38 |
| Sanofi | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Tandem Diabetes Care, Inc. | 1 | $26 |
| AbbVie | 1 | $24 |
| Kaleo, Inc. | 2 | $24 |
| Novartis | 1 | $19 |
| Insulet Corporation | 1 | $17 |
| Mylan Specialty L.p. | 1 | $17 |
| Optinose US, Inc. | 1 | $17 |
| Orexo US, Inc. | 1 | $16 |
| Mannkind Corporation | 1 | $16 |
| Incyte Corporation | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Valeritas, Inc. | 1 | $13 |
| AstraZeneca | 1 | $11 |
How this compares
$1,985 in reported general payments places this provider in the 75th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 12 | $5,778 |
| Duloxetine Hcl | 16 | $2,836 |
| Aripiprazole | 39 | $1,943 |
| Vilazodone Hcl | 16 | $1,472 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 36 | $946 |
| Clonazepam | 39 | $442 |
| Bupropion XlBupropion Hcl | 18 | $393 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 15 | $381 |
| Trazodone Hcl | 33 | $342 |
| Lorazepam | 13 | $256 |
| Zolpidem Tartrate | 13 | $245 |
| Fluvoxamine Maleate | 12 | $202 |
| Sertraline Hcl | 15 | $114 |
| Fluoxetine Hcl | 21 | $97 |
| Alprazolam | 21 | $87 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $28 | $5,77812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Waco
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$5.9M
- Marshall LucasThe Woodlands$4.8M
- Sejal MehtaPlano$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.